Management of Severe Insulin Resistance in Patients with Type 1 Diabetes
The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Abstract
Managing severe insulin resistance (IR) in patients with type 1 diabetes (T1DM) can be challenging for both clinicians and patients. As average weight for patients with T1DM has increased in recent decades, IR in this population has become more widespread. Currently, almost 50 % of patients with T1DM are overweight or obese. While intensive insulin therapy is associated with reduction in complications, aggressive treatment can lead to weight gain. With increasing weight, insulin can become less effective to control glycemia, resulting in higher insulin doses and hence more weight gain. Novel strategies to break this vicious cycle are needed. This review will investigate current research on insulin formulations, lifestyle modification, adjunct therapies, and surgery that may help better manage patients with T1DM and IR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in people with established type 1 diabetes, presence of obesity can worsen insulin resistance, glycemic variability, microvascular disease complications, and cardiovascular risk factors (184 -188).”
From Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report (2019) · cites this paper as [185]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Fuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
Sjöström, L. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12012 · Cited by 1,835
Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes
Mingrone, G., Panunzi, S., De Gaetano, A., Guidone, C., Iaconelli, A., Leccesi, L., Nanni, G., Pomp, A., Castagneto, M., Ghirlanda, G., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200111 · Cited by 1,791
Ogden, C. L., Yanovski, S. Z., Carroll, M. D., & Flegal, K. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.052 · Cited by 1,561
Glycemic Control and Excess Mortality in Type 1 Diabetes
Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408214 · Cited by 964
α-Glucosidase Inhibitors for Patients With Type 2 Diabetes
van de Laar, F. A., Lucassen, P. L., Akkermans, R. P., van de Lisdonk, E. H., Rutten, G. E., & van Weel, C. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.154 · Cited by 690
Wilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., Rohwedder, K., Parikh, S., & for the Dapagliflozin 006 Study Group* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-6-201203200-00003 · Cited by 467
Metabolic Syndrome in Type 1 Diabetes
Thorn, L. M., Forsblom, C., Fagerudd, J., Thomas, M. C., Pettersson-Fernholm, K., Saraheimo, M., Wadén, J., Rönnback, M., Rosengård-Bärlund, M., Björkesten, C.-G. A., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.8.2019 · Cited by 423
Becker, R. H. A., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015) · Diabetes Care · doi:10.2337/dc14-0006 · Cited by 407
Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Kawakubo, M., & Buchanan, T. A. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-1066 · Cited by 402
Heller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., Renard, E., Russell-Jones, D., Philotheou, A., Francisco, A. M. O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60204-9 · Cited by 402
Heise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397
Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes
Heise, T., Nosek, L., Bøttcher, S. G., Hastrup, H., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01638.x · Cited by 331
Temporal patterns in overweight and obesity in type 1 diabetes
Conway, B., Miller, R. G., Costacou, T., Fried, L., Kelsey, S., Evans, R. W., & Orchard, T. J. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02956.x · Cited by 326
Ratner, R. E., Dickey, R., Fineman, M., Maggs, D. G., Shen, L., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01319.x · Cited by 307
Absorption of Injected Insulin: A Clinical‐Pharmacological Study
BINDER, C. (1969) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1969.tb03069.x · Cited by 287
Whitehouse, F., Kruger, D. F., Fineman, M., Shen, L., Ruggles, J. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.724 · Cited by 264
Henry, R. R., Rosenstock, J., Edelman, S., Mudaliar, S., Chalamandaris, A.-G., Kasichayanula, S., Bogle, A., Iqbal, N., List, J., & Griffen, S. C. (2015) · Diabetes Care · doi:10.2337/dc13-2955 · Cited by 238
Perkins, B. A., Cherney, D. Z. I., Partridge, H., Soleymanlou, N., Tschirhart, H., Zinman, B., Fagan, N. M., Kaspers, S., Woerle, H.-J., Broedl, U. C., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2338 · Cited by 231
AMP‐activated protein kinase: role in metabolism and therapeutic implications
Schimmack, G., DeFronzo, R. A., & Musi, N. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00561.x · Cited by 227
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
Sands, A. T., Zambrowicz, B. P., Rosenstock, J., Lapuerta, P., Bode, B. W., Garg, S. K., Buse, J. B., Banks, P., Heptulla, R., Rendell, M., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2806 · Cited by 220
Mathieu, C., Hollander, P., Miranda-Palma, B., Cooper, J., Franek, E., Russell-Jones, D., Larsen, J., Tamer, S. C., Bain, S. C., & on behalf of the NN1250-3770 (BEGIN: Flex T1) Trial Investigators (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3249 · Cited by 219
Pambianco, G., Costacou, T., & Orchard, T. J. (2007) · Diabetes Care · doi:10.2337/dc06-2053 · Cited by 198
Powell, D. R., Smith, M., Greer, J., Harris, A., Zhao, S., DaCosta, C., Mseeh, F., Shadoan, M. K., Sands, A., Zambrowicz, B., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203364 · Cited by 184
Grunberger, G., Abelseth, J. M., Bailey, T. S., Bode, B. W., Handelsman, Y., Hellman, R., Jovanovič, L., Lane, W. S., Raskin, P., Tamborlane, W. V., et al. (2014) · Endocrine Practice · doi:10.4158/ep14145.ps · Cited by 180
Weyer, C., Maggs, D., Young, A., & Kolterman, O. (2001) · Current Pharmaceutical Design · doi:10.2174/1381612013397357 · Cited by 174
Kielgast, U., Krarup, T., Holst, J. J., & Madsbad, S. (2011) · Diabetes Care · doi:10.2337/dc11-0096 · Cited by 165
Impact of Physical Activity on Cardiovascular Risk Factors in IDDM
Lehmann, R., Kaplan, V., Bingisser, R., Bloch, K. E., & Spinas, G. A. (1997) · Diabetes Care · doi:10.2337/diacare.20.10.1603 · Cited by 164
A systematic review and meta-analysis of exercise interventions in adults with type 1 diabetes
Yardley, J. E., Hay, J., Abou-Setta, A. M., Marks, S. D., & McGavock, J. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.09.038 · Cited by 162
Metformin as an Adjunct Therapy in Adolescents With Type 1 Diabetes and Insulin Resistance
Hamilton, J., Cummings, E., Zdravkovic, V., Finegood, D., & Daneman, D. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.138 · Cited by 161
Wallberg-Henriksson, H., Gunnarsson, R., Henriksson, J., DeFronzo, R., Felig, P., Ostman, J., & Wahren, J. (1982) · Diabetes · doi:10.2337/diabetes.31.12.1044 · Cited by 160
Pramlintide in the treatment of type 1 and type 2 diabetes mellitus
Ryan, G. J., Jobe, L. J., & Martin, R. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.10.009 · Cited by 159
Ramalho, A. C., Lima, M. D. L., Nunes, F., Cambuí, Z., Barbosa, C., de Andrade, A. G., Viana, A., Martins, M., Abrantes, V., de Aragão, C., et al. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.11.011 · Cited by 144
Chillarón, J. J., Goday, A., Flores-Le-Roux, J. A., Benaiges, D., Carrera, M. J., Puig, J., Cano-Pérez, J. F., & Pedro-Botet, J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0960 · Cited by 137
Epidemiological evidence for "double diabetes"
Teupe, B., & Bergis, K. (1991) · The Lancet · doi:10.1016/0140-6736(91)90988-2 · Cited by 136
Ellis, S. L., Moser, E. G., Snell-Bergeon, J. K., Rodionova, A. S., Hazenfield, R. M., & Garg, S. K. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03331.x · Cited by 131
Liraglutide as additional treatment for type 1 diabetes
Varanasi, A., Bellini, N., Rawal, D., Vora, M., Makdissi, A., Dhindsa, S., Chaudhuri, A., & Dandona, P. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0330 · Cited by 129
Clemmons, D. R., Moses, A. C., McKay, M. J., Sommer, A., Rosen, D. M., & Ruckle, J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.4.6559 · Cited by 128
High-dose Insulin Therapy: is it Time for U-500 Insulin?
Lane, W. S., Cochran, E. K., Jackson, J. A., Scism-Bacon, J. L., Corey, I. B., Hirsch, I. B., & Skyler, J. S. (2009) · Endocrine Practice · doi:10.4158/ep.15.1.71 · Cited by 127
de la Peña, A., Riddle, M., Morrow, L. A., Jiang, H. H., Linnebjerg, H., Scott, A., Win, K. M., Hompesch, M., Mace, K. F., Jacobson, J. G., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0721 · Cited by 125
Low within‐ and between‐day variability in exposure to new insulin glargine 300 U/ml
Becker, R. H. A., Nowotny, I., Teichert, L., Bergmann, K., & Kapitza, C. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12416 · Cited by 125
Sarnblad, S., Kroon, M., & Aman, J. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1490323 · Cited by 119
Vora, J., Christensen, T., Rana, A., & Bain, S. C. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0076-9 · Cited by 96
Clinical use of U-500 regular insulin: Review and meta-analysis
Reutrakul, S., Wroblewski, K., & Brown, R. L. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600229 · Cited by 94
Self-citationLund, S. S., Tarnow, L., Astrup, A. S., Hovind, P., Jacobsen, P. K., Alibegovic, A. C., Parving, I., Pietraszek, L., Frandsen, M., Rossing, P., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003363 · Cited by 92
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis
Savarese, G., Perrone-Filardi, P., D'Amore, C., Vitale, C., Trimarco, B., Pani, L., & Rosano, G. M. C. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.12.017 · Cited by 90
Korsatko, S., Deller, S., Koehler, G., Mader, J. K., Neubauer, K., Adrian, C. L., Thomsen, H., Haahr, H., & Pieber, T. R. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0096-7 · Cited by 89
Acerini, C. L., Patton, C. M., Savage, M. O., Kernell, A., Westphal, O., & Dunger, D. B. (1997) · The Lancet · doi:10.1016/s0140-6736(97)06467-2 · Cited by 89
Thrailkill, K. M., Quattrin, T., Baker, L., Kuntze, J. E., Compton, P. G., & Martha, P. M. (1999) · Diabetes Care · doi:10.2337/diacare.22.4.585 · Cited by 88
Acarbose in the Treatment of Type I Diabetes
Hollander, P., Pi-Sunyer, X., & Coniff, R. F. (1997) · Diabetes Care · doi:10.2337/diacare.20.3.248 · Cited by 87
The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes
Raman, V. S., Mason, K. J., Rodriguez, L. M., Hassan, K., Yu, X., Bomgaars, L., & Heptulla, R. A. (2010) · Diabetes Care · doi:10.2337/dc09-1959 · Cited by 87
The metabolic syndrome in type 1 diabetes: does it exist and does it matter?
McGill, M. J., Molyneaux, L. M., Twigg, S. M., & Yue, D. K. (2008) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2006.10.005 · Cited by 85
Efficacy and Safety of Metformin for Patients with Type 1 Diabetes Mellitus: A Meta-Analysis
Liu, C., Wu, D., Zheng, X., Li, P., & Li, L. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0190 · Cited by 78
Cheetham, T. D., Jones, J., Taylor, A. M., Holly, J. M. P., Matthews, D. R., & Dunger, D. B. (1993) · Diabetologia · doi:10.1007/bf00404081 · Cited by 78
Cadario, F., Prodam, F., Pasqualicchio, S., Bellone, S., Bonsignori, I., Demarchi, I., Monzani, A., & Bona, G. (2012) · PubMed · doi:10.3275/7755 · Cited by 76
Meyer, L., Bohme, P., Delbachian, I., Lehert, P., Cugnardey, N., Drouin, P., & Guerci, B. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2153 · Cited by 76
Hirsch, I. B., Bode, B., Courreges, J.-P., Dykiel, P., Franek, E., Hermansen, K., King, A., Mersebach, H., & Davies, M. (2012) · Diabetes Care · doi:10.2337/dc11-2503 · Cited by 76
Pitocco, D., Zaccardi, F., Tarzia, P., Milo, M., Scavone, G., Rizzo, P., Pagliaccia, F., Nerla, R., Di Franco, A., Manto, A., et al. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12041 · Cited by 72
Nadeau, K. J., Chow, K., Alam, S., Lindquist, K., Campbell, S., McFann, K., Klingensmith, G., & Walravens, P. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12140 · Cited by 71
The Effect of Metformin in Overweight Patients with Type 1 Diabetes and Poor Metabolic Control
Jacobsen, I. B., Henriksen, J. E., & Beck‐Nielsen, H. (2009) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2009.00380.x · Cited by 69
The Effect of Rosiglitazone on Overweight Subjects With Type 1 Diabetes
Strowig, S. M., & Raskin, P. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1562 · Cited by 64
A low‐fat diet improves peripheral insulin sensitivity in patients with Type 1 diabetes
Rosenfalck, A. M., Almdal, T., Viggers, L., Madsbad, S., & Hilsted, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01810.x · Cited by 63
Saukkonen, T. T., Amin, R., Williams, R. M., Fox, C., Yuen, K. C. J., White, M. A., Umpleby, A. M., Acerini, C. L., & Dunger, D. B. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0243 · Cited by 62
The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes
Khan, A. S. A., McLoughney, C. R., & Ahmed, A. B. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01966.x · Cited by 58
Lane, W. S., Weinrib, S. L., Rappaport, J. M., & Przestrzelski, T. (2010) · Endocrine Practice · doi:10.4158/ep10014.or · Cited by 55
Effect of pioglitazone therapy in lean type1 diabetes mellitus
Bhat, R. V., Bhansali, A. K., Bhadada, S. K., & Sialy, R. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.04.012 · Cited by 53
Davies, M. J., Gross, J. L., Ono, Y., Sasaki, T., Bantwal, G., Gall, M. A., Niemeyer, M., Seino, H., & on behalf of the BEGIN BB T1 study group (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12298 · Cited by 53
Strychar, I., Cohn, J. S., Renier, G., Rivard, M., Aris-Jilwan, N., Beauregard, H., Meltzer, S., Bélanger, A., Dumas, R., Ishac, A., et al. (2009) · Diabetes Care · doi:10.2337/dc08-2322 · Cited by 52
Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes
Zdravković, V., Hamilton, J. K., Daneman, D., & Cummings, E. A. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.08.049 · Cited by 51
Long-Term Results of Gastric Bypass Surgery in Morbidly Obese Type 1 Diabetes Patients
Czupryniak, L., Wiszniewski, M., Szymański, D., Pawłowski, M., Loba, J., & Strzelczyk, J. (2010) · Obesity Surgery · doi:10.1007/s11695-010-0074-6 · Cited by 50
Riccardi, G., Giacco, R., Parillo, M., Turco, S., Rivellese, A. A., Ventura, M. R., Contadini, S., Marra, G., Monteduro, M., Santeusanio, F., et al. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00047.x · Cited by 50
Glycemic control and excess mortality in type 1 diabetes.
Lind, M., Svensson, A., & Rosengren, A. (2015) · PubMed · doi:10.1056/nejmc1415677 · Cited by 48
Safety and Tolerability of Acarbose in the Treatment of Type 1 and Type 2 Diabetes Mellitus
Neuser, D., Benson, A., ckner, A. B., Goldberg, R. B., Hoogwerf, B. J., & Petzinna, D. (2005) · Clinical Drug Investigation · doi:10.2165/00044011-200525090-00003 · Cited by 43
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes
Lamos, E. M., Younk, L. M., & Davis, S. N. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.909407 · Cited by 43
Bulchandani, D. G., Konrady, T., & Hamburg, M. S. (2007) · Endocrine Practice · doi:10.4158/ep.13.7.721 · Cited by 41
Lannoo, M., Dillemans, B., Van Nieuwenhove, Y., Fieuws, S., Mathieu, C., Gillard, P., D’Hoore, A., & Van Der Schueren, B. (2014) · Diabetes Care · doi:10.2337/dc14-0583 · Cited by 40
Petrie, J. R., Chaturvedi, N., Ford, I., Hramiak, I., Hughes, A. D., Jenkins, A. J., E. Klein, B., Klein, R., Ooi, T. C., Rossing, P., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12840 · Cited by 39
de la Peña, A., Ma, X., Reddy, S., Ovalle, F., Bergenstal, R. M., & Jackson, J. A. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814532326 · Cited by 37
Bariatric Surgery for Severe Obesity in Two Adolescents With Type 1 Diabetes
Chuang, J., Zeller, M. H., Inge, T. H., & Crimmins, N. A. (2013) · PEDIATRICS · doi:10.1542/peds.2012-3640 · Cited by 35
Leroux, C., Gingras, V., Desjardins, K., Brazeau, A., Ott-Braschi, S., Strychar, I. M., & RABASA-LHORET, R. P. R. (2015) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.01.004 · Cited by 35
Clinical Experience with U500 Insulin: Risks and Benefits
Boldo, A., & Comi, R. J. (2011) · Endocrine Practice · doi:10.4158/ep11163.or · Cited by 32
Eby, E. L., Wang, P., Curtis, B. H., Xie, J., Haldane, D. C., Idris, I., Peters, A. L., Hood, R. C., & Jackson, J. A. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.772059 · Cited by 31
Tanenberg, R. J., Tanenberg, R. J., & Pories, W. J. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s9981 · Cited by 30
Stone, M., Walker, J. L., Chisholm, D. J., Craig, M. E., Donaghue, K. C., Crock, P., Anderson, D., & Verge, C. F. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00383.x · Cited by 30
Effects of acarbose (Glucobay®) in persons with type 1 diabetes: a multicentre study
Sels, J.-P. J. E., Verdonk, H. E. R., & Wolffenbuttel, B. H. R. (1998) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(98)00070-9 · Cited by 30
Nagai, E., Katsuno, T., Miyagawa, J., Konishi, K., Miuchi, M., Ochi, F., Kusunoki, Y., Tokuda, M., Murai, K., Hamaguchi, T., et al. (2011) · Endocrine Journal · doi:10.1507/endocrj.k11e-129 · Cited by 28
Lane, W. S., Weinrib, S. L., Rappaport, J. M., Hale, C. B., Farmer, L. K., & Lane, R. S. (2012) · Endocrine Practice · doi:10.4158/ep12226.or · Cited by 27
Gastric Bypass Surgery in Severely Obese Type 1 Diabetic Patients
Czupryniak, L., Strzelczyk, J., Cypryk, K., Pawlowski, M., Szymański, D., Lewiñski, A., & Loba, J. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2561 · Cited by 27
Thankamony, A., Tossavainen, P. H., Sleigh, A., Acerini, C. L., Elleri, D., Dalton, R. N., Jackson, N., Umpleby, A. M., Williams, R. M., & Dunger, D. B. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3264 · Cited by 24
Impact of a high-monounsaturated-fat diet on lipid profile in subjects with type 1 diabetes
Strychar, I. M., Ishac, A., Rivard, M., Lussier‐Cacan, S., Beauregard, H., Aris-Jilwan, N., Radwan, F., & Yale, J.-F. (2003) · Journal of the American Dietetic Association · doi:10.1016/s0002-8223(03)00015-4 · Cited by 24
Obesity and metabolic surgery in type 1 diabetes mellitus.
Raab, H., Weiner, R. A., Frenken, M., Kristian, R. E. T. T., & Weiner, S. R. (2013) · PubMed · doi:10.3305/nh.2013.28.sup2.6711 · Cited by 22
Effect of Pioglitazone on the Course of New-Onset Type 1 Diabetes Mellitus
Sue, T. K., Godil, M. A., Harry, L. A., & Allen, W. T. (2013) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.981 · Cited by 22
Influence of acarbose on post-prandial insulin requirements in patients with Type 1 diabetes.
Juntti‐Berggren, L., Pigon, J., Hellström, P. M., Holst, J. J., & Efendić, S. (2000) · PubMed · Cited by 20
Are You Ready for More Insulin Concentrations?
Segal, A. R., & ElSayed, N. A. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814557860 · Cited by 16
Impact of a high-monounsaturated-fat diet on lipid profile in subjects with type 1 diabetes☆☆☆★
Strychar, I. M., Ishac, A., Rivard, M., et al. (2003) · Journal of the American Dietetic Association · doi:10.1053/jada.2003.50066 · Cited by 15
Insulin‐like growth factor‐I for the treatment of type 1 diabetes
Acerini, C. L., & Dunger, D. B. (2000) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00123.x · Cited by 11
Glycemic Control and Hypoglycemia with New Insulin Glargine 300 U/mL in People with T1DM (EDITION 4)
BAJAJ, H. S., Home, P. D., Bergenstal, R. M., Riddle, M. C., Ziemen, M., Rojeski, M., Espinasse, M., & Bolli, G. B. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.07.116 · Cited by 7
Dash, S., Crisp, S. J., Hartnell, S., Donald, S., Davenport, K., Simmons, D. S., & Evans, M. L. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.11.008 · Cited by 6
Bhatnagar, K. S. (1995) · BMJ · doi:10.1136/bmj.310.6975.333 · Cited by 4
Research works printed but not linked: 3
- Garg R, Lawrence IG, Akinsola MO, Davies MJ, McNally PG. Improved glycaemic control in severely insulin resistant, insulin treated diabetic patients with U500 human actrapid over 2 years follow-up. Diabetologia. 2004;47 Suppl 1:A58.
- Nayyar V, Lawrence IG, Kong MF, Gallagher A, Gregory R, Hiles S, et al. Long-term follow-up of patietns on U-500 human actrapid. Diabetologia. 2007;50(Suppl1):S538.
- Matsuhisa M, Koyama M, Cheng X, Shimizu S, Hirose T, EDITION JP1 Study Group. New insulin glargine 300 U/mL: glycemic control and hypoglycemia in Japanese people with T1DM (edition JP 1). Diabetes. 2014;63 Suppl 1:LB22. An open-label study compared Gla-300 vs. Gal-100 in 243 Japanese patients with T1DM for 6 months. Both insulins resulted in similar HbA1c reduction, with less confirmed or severe nocturnal hypoglycemic events with Gla-300, particularly in the first 8 weeks.
Cited by
Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report
Evert, A. B., Dennison, M., Gardner, C. D., Garvey, W. T., Lau, K. H. K., MacLeod, J., Mitri, J., Pereira, R. F., Rawlings, K., Robinson, S., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0014 · Cited by 1,496
Weight management in patients with type 1 diabetes and obesity
Mottalib, A., Kasetty, M., Mar, J. Y., Elseaidy, T., Ashrafzadeh, S., & Hamdy, O. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0918-8 · Cited by 149
Yang, D., Zhou, J., Garstka, M. A., Xu, Q., Li, Q., Wang, L., Ren, L., Ji, Q., & Liu, T. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02736-2 · Cited by 23
“As the cornerstone treatment for T1D, intensive insulin therapy can lead to obesity and insulin resistance [18, 19], both of which play crucial roles in the initiation, progression, and adverse outcomes of atherosclerosis [20, 21].”
Zeng, J., Liu, H.-B., Ping, F., Li, W., & Li, Y. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.02.003 · Cited by 20
McDonald, M. W., Dotzert, M. S., Jiang, M., Murray, M. R., Noble, E. G., & Melling, C. W. J. (2018) · Journal of Diabetes Research · doi:10.1155/2018/8485624 · Cited by 10
“This is a significant question that needs to be answered since IIT is associated with cardiovascular risk factors such as increased sedentary behaviour, weight gain, and insulin resistance [8, 13, 14].”
Background
Metadata
- Authors
- Schechter, R., & Reutrakul, S.
- Affiliations
- Mahidol University (TH)
- Corresponding author
- Reutrakul, Sirimon
- ORCID
- Reutrakul, Sirimon
- Venue
- Current Diabetes Reports
- Published
- 2015-08-21
- Volume
- 15
- Issue
- 10
- Pages
- 77-77
- ISSN
- 1534-4827 (ISSN-L)
- 1539-0829
- OpenAlex
- W1143305783
- Cited by
- 15
- References
- 102
- Citations by year
- 2025: 2 · 2023: 1 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 2
- FWCI
- 0.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Current Diabetes Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin resistance, type 1 diabetes, obesity, weight gain, intensive insulin therapy, insulin formulations, lifestyle modification, adjunctive therapy, bariatric surgery, glycemic control
- MeSH terms
- Diabetes Mellitus, Type 1, Diet, Diet Therapy, Exercise Therapy, Humans, Insulin, Insulin Resistance, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.